NSCI Stock Overview
Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries.
Nanalysis Scientific Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$1.04|
|52 Week High||CA$1.76|
|52 Week Low||CA$0.46|
|1 Month Change||-13.33%|
|3 Month Change||-14.05%|
|1 Year Change||126.09%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||89.09%|
Recent News & Updates
|NSCI||CA Medical Equipment||CA Market|
Return vs Industry: NSCI exceeded the Canadian Medical Equipment industry which returned -35.1% over the past year.
Return vs Market: NSCI exceeded the Canadian Market which returned 4.2% over the past year.
|NSCI Average Weekly Movement||9.2%|
|Medical Equipment Industry Average Movement||13.1%|
|Market Average Movement||9.6%|
|10% most volatile stocks in CA Market||16.4%|
|10% least volatile stocks in CA Market||4.2%|
Stable Share Price: NSCI is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: NSCI's weekly volatility (9%) has been stable over the past year.
About the Company
Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries. It operates through three segments: Nanalysis, RS2D, and Corporate. The company also offers software module packages; manufactures and sells cutting-edge electronics components for precision analytical instruments; and provides monitoring and supporting services for its NMR technologies.
Nanalysis Scientific Fundamentals Summary
|NSCI fundamental statistics|
Is NSCI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NSCI income statement (TTM)|
|Cost of Revenue||CA$5.80m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.019|
|Net Profit Margin||-11.05%|
How did NSCI perform over the long term?See historical performance and comparison
Is Nanalysis Scientific undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: NSCI is unprofitable, so we can't compare its PE Ratio to the North American Medical Equipment industry average.
PE vs Market: NSCI is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NSCI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NSCI is good value based on its PB Ratio (4.1x) compared to the CA Medical Equipment industry average (4.5x).
How is Nanalysis Scientific forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if NSCI's forecast earnings growth is above the savings rate (1.6%).
Earnings vs Market: Insufficient data to determine if NSCI's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NSCI's revenue (47.8% per year) is forecast to grow faster than the Canadian market (6.1% per year).
High Growth Revenue: NSCI's revenue (47.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NSCI's Return on Equity is forecast to be high in 3 years time
How has Nanalysis Scientific performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NSCI is currently unprofitable.
Growing Profit Margin: NSCI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NSCI is unprofitable, and losses have increased over the past 5 years at a rate of 47.5% per year.
Accelerating Growth: Unable to compare NSCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NSCI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.7%).
Return on Equity
High ROE: NSCI has a negative Return on Equity (-7.4%), as it is currently unprofitable.
How is Nanalysis Scientific's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NSCI's short term assets (CA$20.8M) exceed its short term liabilities (CA$8.6M).
Long Term Liabilities: NSCI's short term assets (CA$20.8M) exceed its long term liabilities (CA$5.2M).
Debt to Equity History and Analysis
Debt Level: NSCI has more cash than its total debt.
Reducing Debt: NSCI's debt to equity ratio has reduced from 38.1% to 19.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NSCI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NSCI has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 24.4% each year.
What is Nanalysis Scientific current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NSCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NSCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NSCI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NSCI's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NSCI has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sean Krakiwsky (51 yo)
Mr. Sean Krakiwsky, M.Sc., is Director at QUAD SYSTEMS AG from March 2022. He is the Founder, Chief Executive Officer, President and Director of Nanalysis Scientific Corp. since June 4, 2019 and served as...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD222.71K) is above average for companies of similar size in the Canadian market ($USD168.45K).
Compensation vs Earnings: Sean's compensation has been consistent with company performance over the past year.
Experienced Management: NSCI's management team is considered experienced (2.8 years average tenure).
Experienced Board: NSCI's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NSCI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.2%.
Nanalysis Scientific Corp.'s employee growth, exchange listings and data sources
- Name: Nanalysis Scientific Corp.
- Ticker: NSCI
- Exchange: TSXV
- Founded: NaN
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: CA$97.855m
- Shares outstanding: 94.09m
- Website: https://www.nanalysis.com
Number of Employees
- Nanalysis Scientific Corp.
- Bay 1, 4600 5th Street NE
- T2E 7C3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.